TENX - Tenax Therapeutics Inc
IEX Last Trade
3.91
0.090 2.302%
Share volume: 10,043
Last Updated: Fri 30 Aug 2024 09:39:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.82
0.09
2.36%
Fundamental analysis
26%
Profitability
25%
Dept financing
6%
Liquidity
50%
Performance
26%
Performance
5 Days
-5.45%
1 Month
17.35%
3 Months
14.00%
6 Months
-3.62%
1 Year
-85.54%
2 Year
-98.97%
Key data
Stock price
$3.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.77 - $61.20
52 WEEK CHANGE
-$0.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Anthony DiTonno
Region: US
Website: http://www.tenaxthera.com/
Employees: 16
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.tenaxthera.com/
Employees: 16
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.
Recent news